CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis

Open access

Abstract

Background: Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller and more stable, have been investigated. This study analyzes the gastrointestinal side effects of these newer, smaller molecules. Methods: We performed a systematic review of the literature databases like PubMed, Cochrane, Embase, and clinicaltrials.gov until November 2023. Data related to different doses of oral danuglipron and orforglipron and their gastrointestinal side effects including nausea, vomiting, constipation, diarrhea, eructation, and dyspepsia were obtained. Analysis was done using RevMan v5.4 (The Cochrane Collaboration, Copenhagen, Denmark). Results: We included a total of 4 studies of which 2 each were for danuglipron and orforglipron. The oral doses of orforglipron studied were 12 mg, 24 mg, 36 mg, and 45 mg, with nausea being the most common side effect in all groups. For the 45 mg dose of orforglipron, the odds ratio (OR) was 4.41 (95% CI: 2.90–6.71), while the 36 mg dose had an OR of 3.99 (95% CI: 2.22–7.18). The OR for the 24 mg dose was 5.66 (95% CI: 3.39–9.45), and the 12 mg dose showed an OR of 5.06 (95% CI: 3.31–7.73). Oral danuglipron at doses of 80 mg and 120 mg were also studied. The 120 mg dose of danuglipron had a pooled OR of 4.38 (95% CI: 2.30–8.34) while the 80 mg dose had an OR of 3.69 (95% CI: 1.77–7.67) indicating a significant decrease in gastrointestinal side effects. Conclusion: Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists were widely reported but less frequent compared to placebo/ standard treatment. There was no significant dose-dependent increase in the side effects of these medications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000046671

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Preferred reporting items for systematic reviews and meta‐analyses (PRISMA) flowchart of the included studies.
Figure 1. Preferred reporting items for systematic reviews and meta‐analyses (PRISMA) flowchart of the included studies.CC BY-NC · PubMed Central
Figure 2. Traffic light plot using ROB2 for risk of bias assessment of included studies.
Figure 2. Traffic light plot using ROB2 for risk of bias assessment of included studies.CC BY-NC · PubMed Central
Figure 3. Forest plot showing gastrointestinal side effects of 12 mg orforglipron.
Figure 3. Forest plot showing gastrointestinal side effects of 12 mg orforglipron.CC BY-NC · PubMed Central
Figure 4. Forest plot showing gastrointestinal side effects of 24 mg orforglipron.
Figure 4. Forest plot showing gastrointestinal side effects of 24 mg orforglipron.CC BY-NC · PubMed Central
Figure 5. Forest plot showing gastrointestinal side effects of 36 mg orforglipron.
Figure 5. Forest plot showing gastrointestinal side effects of 36 mg orforglipron.CC BY-NC · PubMed Central
Figure 6. Forest plot showing gastrointestinal side effects of 45 mg orforglipron.
Figure 6. Forest plot showing gastrointestinal side effects of 45 mg orforglipron.CC BY-NC · PubMed Central
Figure 7. Forest plot showing gastrointestinal side effects of 80 mg danuglipron.
Figure 7. Forest plot showing gastrointestinal side effects of 80 mg danuglipron.CC BY-NC · PubMed Central
Figure 8. Forest plot showing gastrointestinal side effects of 120 mg danuglipron.
Figure 8. Forest plot showing gastrointestinal side effects of 120 mg danuglipron.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Lim, Glucagon-Like Peptide 1 Secretion by the L-Cell., Diabetes

Cited by

See all 5

Metadata

Authors
Bhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., Sah, R., Khanal, A., Ahmed, K., & McDonald, P.
Affiliations
  • Dubai Health Authority (AE)
  • Tribhuvan University (NP)
  • Reading Hospital (US)
  • Saint Agnes Hospital (US)
  • Hurley Medical Center (US)
  • Department of Medicine, Frye Regional Medical Center, Hickory, NC
  • St. John's Hospital (US)
  • Boston Medical Center (US)
  • Wake Forest University Health Sciences (US)
Corresponding author
Shah, Sangam
Venue
Medicine
Published
2025-12-26
Volume
104
Issue
52
Pages
e46671
ISSN
  • 0025-7974 (ISSN-L)
  • 1536-5964
OpenAlex
W7117294626
Cited by
5
References
26
Citations by year
2026: 5
FWCI
0.67
Type
journal article
Language
en
Open access
Locations
  • Medicine (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
GLP-1 receptor agonists, orforglipron, gastrointestinal adverse effects, nausea, vomiting, constipation, diarrhea, dyspepsia, eructation, dose-response relationship, oral administration, diabetes mellitus, weight loss, adverse drug reactions, pharmacokinetics, pharmacodynamics, pharmacovigilance
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Dose-Response Relationship, Drug, Gastrointestinal Diseases, Humans, Hypoglycemic Agents, Nausea

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1097/md.0000000000046671
The paper
Bhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., Sah, R., Khanal, A., Ahmed, K., & McDonald, P. (2025). Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis. Medicine. https://doi.org/10.1097/md.0000000000046671

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.